Department of Cardiovascular Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Department of Oncology, Mayo Clinic, Rochester, MN, USA.
Curr Oncol Rep. 2018 Sep 10;20(10):81. doi: 10.1007/s11912-018-0725-7.
This review aims to outline the general principles of how to build a cardio-onco-hematology clinic, acknowledging that there are diverse practices ranging from private community settings to academic hospitals and each practice environment has to build its own program.
The refinement of regimens and introduction of molecularly directed therapies have substantially increased survival rates for patients with cancer. In fact, a number of previous imminently fatal malignant disease processes have been turned into chronic diseases, such that patients now live with certain incurable cancers as they do, for instance, with rheumatoid arthritis. Improved cure rates and longer survivals have raised side effects of cancer treatments to a completely new level of significance. Cardiovascular toxicities are of particular concern given their impact on morbidity and mortality. In most extreme cases, patients might be cured from cancer but remain debilitated or die prematurely because of cardiovascular disease. Furthermore, not an insignificant proportion of cancer patients start cancer therapy with cardiovascular risk factors and diseases at baseline. With the aging of the population, this "joint venture" is only expected to increase with important implications for the management of cancer patients. Given the need for familiarity with both, cancer and cardiovascular diseases and their ever-evolving start-of-the-art therapy and interaction potential, specialized efforts have been invoked, which may collectively be termed "onco-cardiology," "cardio-oncology," or "cardio-onco-hematology." Herein, we provide recommendations for the creation and optimization of any such programmatic efforts.
本篇综述旨在概述建立心脏肿瘤血液病诊所的一般原则,需要承认的是,从私人社区环境到学术医院,各种实践模式差异显著,并且每种实践环境都必须建立自己的项目。
治疗方案的完善和分子靶向治疗的引入,大大提高了癌症患者的生存率。事实上,许多以前致命的恶性疾病过程已经转变为慢性疾病,例如,某些无法治愈的癌症患者,如类风湿关节炎患者一样,能够带病生存。治愈率的提高和生存时间的延长,使癌症治疗的副作用上升到一个全新的重要水平。心血管毒性尤其令人关注,因为它们会影响发病率和死亡率。在大多数极端情况下,患者可能因癌症而治愈,但由于心血管疾病而身体虚弱或过早死亡。此外,相当一部分癌症患者在基线时就存在心血管风险因素和疾病,开始癌症治疗。随着人口老龄化,这种“合资企业”预计只会增加,这对癌症患者的管理具有重要意义。鉴于对癌症和心血管疾病及其不断发展的前沿治疗方法和相互作用的熟悉,已经进行了专门的努力,这些努力可以统称为“肿瘤心脏病学”、“心脏肿瘤学”或“心脏肿瘤血液病学”。在此,我们为任何此类计划工作的创建和优化提供了建议。